Document is current
Any future updates will be listed below
-
Authors
Nanaa, Muzna
Manavaki, Roido
van Nijnatten, Thiemo J. A.
Stranz, Natalia
Carriero, Serena
Coleman, William A.
Allajbeu, Iris
Payne, Nicholas R.
Giannotti, Elisabetta
Hickman, Sarah E.
Arponen, Otso
Gilbert, Fiona J. https://orcid.org/0000-0002-0124-9962
-
Funding
Funding for this research was provided by:
Cancer Research UK
NIHR Cambridge Biomedical Research Centre ((BRC-1215-20014))
Cara (210211)
- License Information
-
More Information
Article History
Received: 2 September 2024
Revised: 21 November 2024
Accepted: 7 December 2024
First Online: 21 January 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Professor Fiona J. Gilbert.
: The authors of this manuscript declare relationships with the following companies: F.J.G. receives research support from Hologic, GE Healthcare, Bayer, and Lunit. F.J.G., N.R.P., S.E.H., and M.N. have research collaborations with Vara, Screen-Point, Lunit, Google, Volpara, iCAD, Therapixel, CureMetrix, Sunnybrook Research Institute, and Massachusetts Institute of Technology.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study because it was covered by ethical approvals.
: Ethical approval was obtained from the National Research Ethics Committee (NRES Committee London, UK; REC number: 20/LO/0104), Health Research Authority Research Confidentiality Advisory Group (ref no: 20/CAG/0009), and Public Health England (PHE) Research Advisory Committee (ref no: BSPRAC_090).
: Some study subjects or cohorts have been previously reported in: MacInnes et al [] and Hickman et al []. However, the focus of the work presented in the above publications and the submitted manuscript is different. MacInnes et al reported 60 out of 476 interval cancers included in this study, between 2008 and 2016, using interval cancers that were classified as either suspicious or with minimal signs of malignancy from five UK centres to estimate interval cancer growth rates, while our manuscript uses all interval cancers screened between 2011 and 2018 from one UK centre. Hickman et al reported 131 of the 476 interval cancers included in this study to investigate if deep learning algorithms can be used to triage screening mammograms from two sites. The current study incorporates interval cancers (n = 666) over 7 years at one site to estimate tumour growth rate. Preliminary results from this research have also been presented in abstract form at the European Congress of Radiology (ECR) 2024, Vienna, Austria [Nanaa et al, oral session number: PRS 1202; poster number: C-23605].
:
